Momotaro-Gene is focused on innovative cancer therapies, particularly through the development of gene-based treatments. The company has announced a pending patent for a method of treating liver cancer that combines the REIC/Dkk-3 gene with anti-tumor agents. This approach aims to enhance the efficacy of existing treatments by leveraging the unique properties of the REIC/Dkk-3 gene, which is believed to play a significant role in tumor suppression.

Additionally, Momotaro-Gene has reported on the results of a Phase I/IIa clinical trial involving Ad-SGE-REIC, targeting malignant glioma. Conducted at Okayama University Hospital, this trial represents a significant step in evaluating the safety and effectiveness of this gene therapy approach. The company is also pursuing a patent for a combination therapy that utilizes Ad-REIC/Dkk-3 alongside checkpoint inhibitors for the treatment of thoracic cancers, indicating a robust pipeline of research aimed at addressing various cancer types through advanced genetic strategies.

Japan

Momotaro-Gene is a biotech start-up company from Okayama University whose main technology lies in tumour suppressor gene. They are focused on the development of a next-generation cancer drug.

Momotaro-Gene

Company Details